- Conditions
- Primary Progressive Aphasia
- Interventions
- Communication Bridge™, Evidence-Based Impairment Focused
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 153
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer Disease
- Interventions
- AstroStem, Placebo-Control
- Drug · Other
- Lead sponsor
- Nature Cell Co. Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Costa Mesa, California • Santa Ana, California • Honolulu, Hawaii
- Conditions
- Alzheimer Disease
- Interventions
- AC-OLE-01-VA
- Drug
- Lead sponsor
- Cerecin
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Alzheimer's Disease
- Interventions
- Bryostatin 1, Placebo
- Drug · Other
- Lead sponsor
- Neurotrope Bioscience, Inc.
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Costa Mesa, California • Los Alamitos, California + 26 more
- Conditions
- Health Behavior
- Interventions
- Stress Management Control, Adapted MBC2 Program
- Behavioral
- Lead sponsor
- Nancy Schoenberg
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 279 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Benham, Kentucky
- Conditions
- Alzheimer's Disease
- Interventions
- Gantenerumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 799 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 21 more
- Conditions
- Alzheimer's Disease
- Interventions
- caprylic triglyceride, long-chain triglyceride
- Drug
- Lead sponsor
- Cerecin
- Industry
- Eligibility
- 55 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Alzheimer's Disease, Sleep Disorder
- Interventions
- Circadin, Placebo
- Drug
- Lead sponsor
- Neurim Pharmaceuticals Ltd.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 4
- States / cities
- Brooksville, Florida • St. Petersburg, Florida • Mount Arlington, New Jersey + 1 more
- Conditions
- Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
- Interventions
- Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
- Biological
- Lead sponsor
- AC Immune SA
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more
- Conditions
- Agitation, Alzheimer Disease
- Interventions
- BMS-986368, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 60
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Phoenix, Arizona + 52 more
- Conditions
- Alzheimer Disease
- Interventions
- Rivastigmine 5 cm^2, Rivastigmine 10 cm^2, Rivastigmine 15 cm^2, Placebo to 15 cm^2 patch, Placebo to 10 cm^2 patch
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 1,584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 61 more
- Conditions
- Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
- Interventions
- Brexpiprazole, OPC-34712, Placebo Oral Tablet
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 433 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 37
- States / cities
- Tuscaloosa, Alabama • Phoenix, Arizona • Bellflower, California + 25 more
- Conditions
- Agitation Associated With Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
- Interventions
- Not listed
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 28
- States / cities
- Tuscaloosa, Alabama • Costa Mesa, California • Lakewood, California + 21 more
- Conditions
- Alzheimer's Disease
- Interventions
- T-817MA-H, T-817MA-L, Placebo
- Drug
- Lead sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 46 more
- Conditions
- Dementia, Alzheimer's Type, Alzheimer's Disease
- Interventions
- SAR448851, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 14
- States / cities
- Long Beach, California • Oakland, California • Naples, Florida + 11 more
- Conditions
- Caregiver Burden, Alzheimer Disease
- Interventions
- Brain CareNotes, Dementia Guide Expert
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI)
- Interventions
- Florbetapir, Flortaucipir
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 1,182 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 43 more
- Conditions
- Cognitive Dysfunction
- Interventions
- GE-287, Vizamyl
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 50 Years to 110 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Aventura, Florida • Merritt Island, Florida • Miami, Florida + 2 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Aerobic Exercise
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Alzheimer Disease
- Interventions
- Placebo, PAZ-417
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
- Interventions
- Donanemab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Carlsbad, California + 36 more
- Conditions
- Alzheimer's Disease, Agitation
- Interventions
- Not listed
- Lead sponsor
- Avera McKennan Hospital & University Health Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Alzheimer's Disease, Central Nervous System Diseases, Cognition
- Interventions
- EVP-6124, Placebo
- Drug
- Lead sponsor
- FORUM Pharmaceuticals Inc
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Chino, California • Costa Mesa, California + 21 more
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
- Interventions
- Biological Sample Collection
- Other
- Lead sponsor
- New York Stem Cell Foundation Research Institute
- Other
- Eligibility
- 30 Days and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2045
- U.S. locations
- 1
- States / cities
- New York, New York